Suven Pharma to merge with Cohance Lifesciences
Upon the scheme becoming effective, all shareholders of Cohance will be issued 11 shares of Suven for every 295 shares held in the former, Suven Pharmaceuticals said in a statement.
The transaction is expected to conclude over the next 12-15 months, subject to receipt of all relevant shareholder and regulatory approvals. Image Courtesy: Reuters.